(CercleFinance.com) – Biosynex announces the conclusion by ProciseDx, its subsidiary specializing in the development of a delocalized biology system, of a strategic agreement with Revvity Euroimmun US for the exclusive distribution of its platform on the American and Canadian markets.
The ProciseDx platform is the first to have received de novo authorization from the FDA in September 2023 for dosage tests of Remicade, Humira and their biosimilars used in therapeutic drug monitoring.
PociseDx will rely on Euroimmun US in the distribution of in vitro diagnostic systems to target key market segments. In addition, she will maintain direct access to around thirty prospects with whom she has initiated referencing discussions.